Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | USP19 | O94966 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081558 | 0.85 | CCR5 (0.51) | CCR5SMN1; SMN2NPC1RAB9AOPRD1 | |
| SCHEMBL5081555 | 0.84 | CCR5 (0.51) | CCR5SMN1; SMN2NPC1RAB9AOPRD1 | |
| SCHEMBL4461843 | 0.83 | CCR5 (0.60) | CCR5SMN1; SMN2NPC1RAB9AOPRD1 | |
| SCHEMBL4465069 | 0.81 | CCR5 (0.51) | CCR5SMN1; SMN2NPC1RAB9AOPRD1 | |
| SCHEMBL13597265 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AFAAHCYP2C19 | |
| SCHEMBL13604578 | 0.76 | CCR5 (0.57) | CCR5 | |
| SCHEMBL4458368 | 0.72 | CCR5 (0.49) | CCR5SMN1; SMN2NPC1RAB9AFAAH | |
| SCHEMBL27012546 | 0.72 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13519706 | 0.72 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AFAAHCYP2C19 | |
| SCHEMBL13661148 | 0.71 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AFAAHCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885SMN1; SMN2 1980/4885NPC1 2064/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885SMN1; SMN2 1980/4885NPC1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.